Perhaps not unusually, but there is some evidence that they are more profitable than comparably sized non-pharma companies.
>"from 2000 to 2018, the median net income (earnings) expressed as a fraction of revenue was significantly greater for pharmaceutical companies compared with nonpharmaceutical companies (13.8% vs 7.7%)."
Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies
https://web.archive.org/web/20141227030211/http://www.cff.or... https://en.wikipedia.org/wiki/Ivacaftor#Economics
Hard to argue that the $3.15 billion is a development cost.
I guess Vertex could have dumped billions more into making and marketing the combination.